Working… Menu

Anti-VEGF Treatment for Prevention of PDR/DME

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02634333
Recruitment Status : Active, not recruiting
First Posted : December 18, 2015
Last Update Posted : July 23, 2020
Regeneron Pharmaceuticals
Juvenile Diabetes Research Foundation
National Eye Institute (NEI)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Jaeb Center for Health Research

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : May 2020
Estimated Study Completion Date : May 2022
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 June 21, 2021
July 12, 2021